Specifications for active pharmaceutical ingredients (APIs) and pharmaceutical drug products, both chemical drugs and biologics, are essential for product quality and patient protection. The goals of specification setting are (1) to determine appropriate and safe limits or quantitative ranges during clinical development and (2) to justify specifications for the product to enter the market. One of the most difficult challenges in establishing and subsequently justifying specifications is achieving the appropriate balance among all factors – patient safety and efficacy, scientific data, analytical variability, process knowledge and capability, regulatory requirements, and business issues.
The approach to specification setting and their justification has undergone significant change. Strategic international ICH regulatory guidances have been adopted that are driving the entire pharmaceutical industry, including both chemical drugs and biologics, to a higher standard of performance, including Quality by Design (QbD), Quality Risk Management (QRM) and Pharmaceutical Quality System (PQS).
Therefore, it is most important for a pharmaceutical company to have an effective and regulatory compliant approach to setting specifications that can meet both FDA and EMA requirements and expectations. At each stage of drug development, from Phase 1 through commercialization, the basic question needs to be addressed: ‘What is absolutely necessary for the assigned specification to be successful in getting the chemical drug/biologic through clinical trials and into the market, but without impacting patient safety or creating delays in the program?’ Of equal importance is the need to justify which quality attributes do not need an assigned specification. Regulatory compliant deficiencies in assigned specifications have resulted in clinical holds and market approval delays.
This course will help the attendee to establish specifications meeting global regulatory requirements and expectations. Participants will also become effective in justification of specifications.
This course has been pre-approved by the Regulatory Affairs Professionals Society (RAPS) as eligible for 12 credits towards a participant's RAC recertification upon full completion.
Who Should Attend
This course is designed for those engaged in R&D, Regulatory Affairs, Quality Assurance and Quality Control who are responsible for activities in the development and manufacture of Active Pharmaceutical Ingredient (API) and Drug Products. Personnel who desire an in-depth knowledge of the critical role of specifications and the importance of USP compendial requirements, FDA regulations and ICH guidelines, as well as the relationship between ICH Guidelines and the Common Technical Document (CTD) will find this course of great value.
This comprehensive three-day course is also beneficial to R&D personnel responsible for the use of specifications in conducting Quality by Design (QbD) development of both API and Drug Products.
The course is also of interest to personnel in all departments who participate in the support of manufacture and release of APIs and Drug Products. This includes development personnel in preparing API and Drug Product under cGMP protocols for clinical and non-clinical use, as well as analytical chemists involved with stability testing, assays, methods development and drug release.
At the end of the two-day course attendees will:
- Gain a solid understanding of the regulatory compliance requirements and expectations (FDA, EMA, ICH) for API and drug product specifications, for both chemical drugs and biologics
- Have the tools and understanding to establish regulatory compliant specifications that are clinical phase-appropriate, incorporating Quality Risk Management (QRM)
- Understand the ICH Q8, Q9 and Q10 Quality by Design (QbD) approach applied to setting specifications as part of an effective control system
- Be able to appropriately package specifications and their justification into Module 2.3 and Module 3 of the Common Technical Document (CTD)
- Learn how to avoid major delays in clinical development or market approval due to ineffective setting of specifications